Free Trial

20 Stocks Wall Street Analysts Love the Most - 17 of 20

 
 

Zoetis (NYSE:ZTS)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$221.44 (26.8% Upside)

About Zoetis

Zoetis logoZoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/11/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$225.00 ➝ $230.00
9/18/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$200.00 ➝ $210.00
8/27/2024Stifel NicolausReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/14/2024Piper SandlerBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.00
8/12/2024BTIG ResearchBoost Price TargetBuy ➝ Buy$220.00 ➝ $225.00
8/9/2024ArgusUpgradeStrong-Buy
8/5/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$180.00 ➝ $200.00
7/25/2024BTIG ResearchInitiated CoverageBuy$220.00
5/8/2024HSBCLower Price TargetBuy ➝ Buy$230.00 ➝ $225.00
5/6/2024The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$223.00 ➝ $196.00
 

Trump’s Back, but DC’s Coming for Your Money! (Ad)

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov